Clinical Report: VI-RADS Diagnostic Accuracy for Muscle-Invasive Bladder Cancer

Overview

This systematic review and meta-analysis evaluated the diagnostic performance of the Vesical Imaging Reporting and Data System (VI-RADS) in distinguishing muscle-invasive bladder cancer (MIBC) from non-muscle invasive bladder cancer (NMIBC) using multiparametric MRI before TURBT. The pooled data demonstrated high sensitivity and specificity across different MRI scanners, readers’ experience, and VI-RADS cut-off thresholds, supporting its clinical utility.

Background

Bladder cancer staging critically influences treatment decisions, particularly distinguishing NMIBC from MIBC. VI-RADS is a standardized 5-point mpMRI scoring system developed to predict muscle invasion preoperatively. Although preliminary meta-analyses showed promising accuracy, limitations included small sample sizes and heterogeneity in MRI protocols and reader expertise. This comprehensive review aimed to clarify VI-RADS diagnostic accuracy, reproducibility, and optimal cut-off thresholds to guide future clinical guidelines.

Data Highlights

Key Findings

• VI-RADS demonstrates excellent pooled diagnostic accuracy in discriminating NMIBC from MIBC pre-TURBT.
• Both VI-RADS cut-offs (≥3 and ≥4) provide high sensitivity and specificity, with some variability depending on clinical context.
• Reproducibility is maintained across different MRI scanners (1.5T and 3T) and among readers with varying GU-MRI experience.
• Standardized MRI acquisition protocols consistent with original VI-RADS guidelines are critical for reliable scoring.
• VI-RADS shows promise for guiding therapeutic decisions including selection for secondary resection and neoadjuvant treatment response assessment.

Clinical Implications

VI-RADS can be reliably integrated into preoperative bladder cancer staging workflows to improve identification of muscle invasion, potentially reducing unnecessary invasive procedures. Clinicians should ensure adherence to standardized MRI protocols and consider reader expertise to optimize diagnostic accuracy. The choice of VI-RADS cut-off should be tailored to clinical scenarios balancing sensitivity and specificity.

Conclusion

This comprehensive meta-analysis confirms VI-RADS as a robust, reproducible tool for pre-TURBT staging of bladder cancer, supporting its incorporation into clinical guidelines. Further prospective studies are warranted to refine cut-off thresholds and expand its predictive applications.

References

1. Panebianco et al. 2021 -- Evaluating the Effectiveness of VI-RADS: A Comprehensive Multi-Institutional Systematic Review and Meta-Analysis